Publications in OpenAlex of which a co-author is affiliated to this organization
All publications | By field | By subfield
All publications [Next]
| Title | DOI |
|---|---|
| https://doi.org/10.1093/eurheartj/ehw543 | Cardiopoietic cell therapy for advanced ischemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial |
| https://doi.org/10.1093/eurheartj/ehx248 | Global position paper on cardiovascular regenerative medicine |
| https://doi.org/10.1002/ejhf.898 | Benefit of Cardiopoietic Mesenchymal Stem Cell Therapy on Left Ventricular Remodelling: Results from the Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) Study |
| https://doi.org/10.1016/s2352-3026(22)00378-7 | CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial |
| https://doi.org/10.1016/j.jtho.2016.08.120 | Safety and Immunogenicity of the PRAME Cancer Immunotherapeutic in Patients with Resected Non–Small Cell Lung Cancer: A Phase I Dose Escalation Study |
| https://doi.org/10.1002/ejhf.434 | Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) Trial Design |
| https://doi.org/10.3390/cells13020146 | Allogeneic CAR-T Therapy Technologies: Has the Promise Been Met? |
| https://doi.org/10.1007/s40259-019-00368-z | Chimeric Antigen Receptor-T Cells for Targeting Solid Tumors: Current Challenges and Existing Strategies |
| https://doi.org/10.2217/fon-2017-0102 | Exploiting natural killer group 2D receptors for CAR T-cell therapy |
| https://doi.org/10.1007/s00109-019-01859-w | The integrated stress response promotes B7H6 expression |
| https://doi.org/10.1016/s0140-6736(25)01030-x | In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma |
| https://doi.org/10.3389/fimmu.2024.1411393 | Engineering strategies to safely drive CAR T-cells into the future |
| https://doi.org/10.1200/jco.2021.39.3_suppl.74 | Updated data from alloSHRINK phase I first-in-human study evaluating CYAD-101, an innovative non-gene edited allogeneic CAR-T in mCRC. |
| https://doi.org/10.3389/fimmu.2018.02940 | Overcoming Target Driven Fratricide for T Cell Therapy |
| https://doi.org/10.1097/cji.0000000000000413 | Clinical Grade Manufacture of CYAD-101, a NKG2D-based, First in Class, Non–Gene-edited Allogeneic CAR T-Cell Therapy |
| https://doi.org/10.1002/ejhf.809 | New Medicinal Products for Chronic Heart Failure: Advances in Clinical Trial Design and Efficacy Assessment |
| https://doi.org/10.1182/blood-2019-128267 | Interim Results from the Phase I Deplethink Trial Evaluating the Infusion of a NKG2D CAR T-Cell Therapy Post a Non-Myeloablative Conditioning in Relapse or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients |
| https://doi.org/10.1038/s41375-025-02767-4 | Downregulation of MICA/MICB improves cell persistence and clinical activity of NKG2DL CAR T-cells in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic neoplasia |
| https://doi.org/10.3324/haematol.2017.186742 | NKG2D-based chimeric antigen receptor therapy induced remission in a relapsed/refractory acute myeloid leukemia patient |
| https://doi.org/10.1136/esmoopen-2016-000068 | Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study |
| https://doi.org/10.1016/j.jcyt.2018.05.001 | Manufacturing development and clinical production of NKG2D chimeric antigen receptor–expressing T cells for autologous adoptive cell therapy |
| https://doi.org/10.1002/ejhf.829 | The Effect of Intracoronary Infusion of Bone Marrow-Derived Mononuclear Cells on All-Cause Mortality in Acute Myocardial Infarction: Rationale and Design of the BAMI Trial |
| https://doi.org/10.1136/bmjopen-2017-017075 | Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types |
| https://doi.org/10.1016/j.breast.2019.12.002 | Expression of tumor-associated antigens in breast cancer subtypes |
| https://doi.org/10.1182/blood.v128.22.4052.4052 | Safety Data from a First-in-Human Phase 1 Trial of NKG2D Chimeric Antigen Receptor-T Cells in AML/MDS and Multiple Myeloma |
| https://doi.org/10.1016/j.msec.2019.109751 | A bioresorbable biomaterial carrier and passive stabilization device to improve heart function post-myocardial infarction |
| https://doi.org/10.1007/s10549-016-3751-x | A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors |
| https://doi.org/10.1177/0885328218805878 | Advanced Material Catheter (AMCath), a minimally invasive endocardial catheter for the delivery of fast-gelling covalently cross-linked hyaluronic acid hydrogels |
| https://doi.org/10.1182/blood-2018-99-111326 | Remissions in Relapse/Refractory Acute Myeloid Leukemia Patients Following Treatment with NKG2D CAR-T Therapy without a Prior Preconditioning Chemotherapy |
| https://doi.org/10.1182/blood-2019-128020 | Results from the Completed Dose-Escalation of the Hematological Arm of the Phase I Think Study Evaluating Multiple Infusions of NKG2D-Based CAR T-Cells As Standalone Therapy in Relapse/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients |
| https://doi.org/10.1007/s10549-017-4130-y | Safety and immunogenicity of neoadjuvant treatment using WT1-immunotherapeutic in combination with standard therapy in patients with WT1-positive Stage II/III breast cancer: a randomized Phase I study |
| https://doi.org/10.1182/blood-2021-147738 | Immunicy-1: Targeting BCMA with Cyad-211 to Establish Proof of Concept of an shRNA-Based Allogeneic CAR T Cell Therapy Platform |
| https://doi.org/10.1016/j.omtn.2023.102038 | Efficient shRNA-based knockdown of multiple target genes for cell therapy using a chimeric miRNA cluster platform |
| https://doi.org/10.1200/jco.2016.34.15_suppl.tps3102 | A first-in-human phase I trial of NKG2D chimeric antigen receptor-T cells in AML/MDS and multiple myeloma. |
| https://doi.org/10.1182/blood-2020-139667 | First Results from the Dose Escalation Segment of the Phase I Clinical Study Evaluating Cyad-02, an Optimized Non Gene-Edited Engineered NKG2D CAR T-Cell Product, in Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients |
| https://doi.org/10.1182/blood-2019-129998 | Next Generation NKG2D-based CAR T-cells (CYAD-02): Co-expression of a Single shRNA Targeting MICA and MICB Improves Cell Persistence and Anti-Tumor Efficacy in vivo |
| https://doi.org/10.1200/jco.2022.40.4_suppl.tps227 | KEYNOTE-B79 phase 1b trial to evaluate the allogeneic CAR T-cells CYAD-101 and pembrolizumab in refractory metastatic colorectal cancer patients. |
| https://doi.org/10.3390/ijms26041658 | Clinical Proof-of-Concept of a Non-Gene Editing Technology Using miRNA-Based shRNA to Engineer Allogeneic CAR T-Cells |
| https://doi.org/10.1136/jitc-2021-sitc2021.107 | 107 Armoring NKG2D CAR T cells with IL-18 improves in vivo anti-tumor activity |
| https://doi.org/10.1038/s41591-026-04244-6 | In vivo generation of anti-BCMA CAR-T cells in relapsed or refractory multiple myeloma: a phase 1 study |
| https://doi.org/10.1016/j.retram.2018.03.001 | Celyad's novel CAR T-cell therapy for solid malignancies |
| https://doi.org/10.1136/esmoopen-2017-000203 | Safety and immunogenicity of MAGE-A3 cancer immunotherapeutic with dacarbazine in patients with MAGE-A3-positive metastatic cutaneous melanoma: an open phase I/II study with a first assessment of a predictive gene signature |
| https://doi.org/10.2217/bmm.15.31 | Cardiopoietic Index Predicts Heart Repair Fitness of Patient-Derived Stem Cells |
| https://doi.org/10.3791/58492 | A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells |
| https://doi.org/10.1093/annonc/mdz157.008 | Phase 1 studies assessing the safety and clinical activity of autologous and allogeneic NKG2D-based CAR-T therapy in metastatic colorectal cancer |
| https://doi.org/10.2217/imt-2017-0045 | ‘Atypical’ CAR T Cells: NKG2D and Erb-B as Examples of Natural Receptor/Ligands to Target Recalcitrant Solid Tumors |
| https://doi.org/10.1200/jco.2018.36.15_suppl.e15042 | TCR inhibitory molecule as a promising allogeneic NKG2D CAR-t cell approach. |
| https://doi.org/10.1182/blood-2021-152413 | Co-Expression of an shRNA Targeting MICA/Micb Improves the Clinical Activity of a NKG2D-Based CAR T in Patients with Relapsed / Refractory AML/MDS |
| https://doi.org/10.3389/fimmu.2025.1557405 | Tandem CAR T-cells targeting CD19 and NKG2DL can overcome CD19 antigen escape in B-ALL |
| https://doi.org/10.1002/jbm.a.36353 | Optimization of cell growth on palmitoyl‐hyaluronan knitted scaffolds developed for tissue engineering applications |
| https://doi.org/10.1182/blood-2020-139609 | Results from the Phase I Clinical Studies Evaluating Cyad-01, a First-Generation NKG2D CAR T-Cell Product in Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients |
| https://doi.org/10.1093/annonc/mdy288.052 | The high expression of NKG2D ligands on tumor and the lack of surface expression on healthy tissues provides a strong rationale to support NKG2D-based therapeutic approaches for cancer |
| https://doi.org/10.1136/jitc-2023-sitc2023.0285 | 285 Proof-of-concept of a non-gene editing technology using shRNA down-regulation to engineer and optimize CAR T-cell functionality |
| https://doi.org/10.1200/jco.2020.38.15_suppl.3032 | CYAD-101: An innovative non-gene edited allogeneic CAR-T for solid tumor cancer therapy. |
| https://doi.org/10.1182/blood-2020-139516 | Clinical Development of a Non-Gene-Edited Allogeneic Bcma-Targeting CAR T-Cell Product in Relapsed or Refractory Multiple Myeloma |
| https://doi.org/10.3791/58492-v | A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells |
| https://doi.org/10.1182/blood-2018-99-114747 | Phase 1 Studies Assessing the Safety and Clinical Activity of Multiple Doses of a NKG2D-Based CAR-T Therapy, Cyad-01, in Acute Myeloid Leukemia |
| https://doi.org/10.1158/1538-7445.am2018-ct134 | Abstract CT134: A phase I study assessing the safety and clinical activity of multiple hepatic transarterial administrations of a NKG2D-based CAR-T therapy CYAD-01, in patients with unresectable liver metastases from colorectal cancer |
| https://doi.org/10.1093/annonc/mdy288.051 | Tackling fratricide to manufacture clinical grade NKG2D-CAR T cells for cancer therapy |
| https://doi.org/10.1136/jitc-2023-sitc2023.0232 | 232 NKG2D-based multi-specific CAR T-cells to overcome antigen escape and improve anti-tumor efficacy |
| https://doi.org/10.1136/jitc-2024-sitc2024.0262 | 262 PSMA/NKG2DL tandem CAR T-cells to overcome antigen heterogeneity and improve anti-tumor efficacy against prostate cancer |
| https://doi.org/10.1016/j.jcyt.2025.03.506 | CAR T cells re-directed by a rationally designed human peptide tag demonstrate efficacy in preclinical models |
| https://doi.org/10.1200/jco.2017.35.15_suppl.tps3093 | A NKG2D-based CAR-T therapy in a multinational phase I dose escalation and expansion study targeting multiple solid and hematologic tumor types. |
| https://doi.org/10.1158/1538-7445.am2018-ct123 | Abstract CT123: A phase I study assessing the safety and clinical activity of multiple doses of a NKG2D-based CAR-T therapy, CYAD-01, administered concurrently with the neoadjuvant FOLFOX treatment in patients with potentially resectable liver metastases from colorectal cancer |
| https://doi.org/10.1136/esmoopen-2018-000384 | Association of homogeneous inflamed gene signature with a better outcome in patients with metastatic melanoma treated with MAGE-A3 immunotherapeutic |
| https://doi.org/10.1093/annonc/mdy281.157 | Phase I studies assessing the safety and clinical activity of multiple doses of a NKG2D-based CAR-T therapy, CYAD-01, in metastatic colorectal cancer |
| https://doi.org/10.1097/01.hs9.0000563128.12669.08 | PS1211 CD22 CAR T-CELL THERAPY IN 34 REFRACTORY OR RELAPSED B ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS |
| https://doi.org/10.1136/jitc-2021-sitc2021.146 | 146 Evolving Mutliplexed shRNA to generate tailored CAR T cell therapy |
| https://doi.org/10.1200/jco.2020.38.15_suppl.3103 | Single vector multiplexed shRNA provides a non-gene edited strategy to concurrently knockdown the expression of multiple genes in CAR T cells. |
| https://doi.org/10.20944/preprints202311.2011.v1 | Allogeneic CAR-T Therapy Technologies: Has the Promise Been Met? |
| https://doi.org/10.1016/s1525-0016(16)32880-5 | 71. Validation of Manufacturing NKG2D Chimeric Antigen Receptor T Cells for a First-In-Human Clinical Trial in AML/MDS and Multiple Myeloma |
| https://doi.org/10.1093/annonc/mdx376.063 | Functional screening of B7H6-based chimeric antigen receptor (CAR) designs |
| https://doi.org/10.1158/1538-7445.am2018-3583 | Abstract 3583: NKG2D as a chimeric antigen receptor - DAP 10 provides optimal co stimulation for NKG2D based CARs |
| https://doi.org/10.1200/jco.2018.36.15_suppl.e15040 | Development of an allogeneic product by CAR-T cells TCR knock-down. |
| https://doi.org/10.1007/978-1-4939-9450-2_13 | Identifying Antigens Recognized by Cytolytic T Lymphocytes on Tumors |
| https://doi.org/10.1097/01.hs9.0000563124.05046.27 | PS1210 DEVELOPMENT OF A NEXT GENERATION ALLOGENEIC CAR‐T CELL PLATFORM WITHOUT GENE EDITING |
| https://doi.org/10.1097/01.hs9.0000563136.89798.39 | PS1213 SEQUENTIAL CD19‐ AND CD22‐DIRECTED CAR‐T CELL THERAPIES IN 11 REFRACTORY OR RELAPSED B‐ALL CHILDREN PATIENTS |
| https://doi.org/10.1097/01.hs9.0000562204.35594.cc | PS975 HIGH‐RESOLUTION CLONAL ANALYSIS OF TUMORS WITH SIMULTANEOUS SINGLE‐CELL DNA SEQUENCING AND CELL SURFACE PHENOTYPING |
| https://doi.org/10.1097/01.hs9.0000563132.89798.2c | PS1212 UPDATED RESULTS FROM PHASE I TRIALS ASSESSING A NKG2D CAR T‐CELL APPROACH IN RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME PATIENTS |
| Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) trial design: CHART-1 trial design | |
| https://doi.org/10.1136/jitc-2021-sitc2021.407 | 407 A phase 1b KEYNOTE-B79 trial evaluating non-gene edited allogeneic CAR T-cells, CYAD-101, post FOLFOX preconditioning, followed by pembrolizumab, in refractory metastatic colorectal cancer patients |
| https://doi.org/10.1093/annonc/mdy485.006 | Pooling signaling and costimulatory domains in a flexible CARpool design |
| https://doi.org/10.1136/jitc-2023-sitc2023.0231 | 231 Differential effects of target ligands and receptor architecture upon NKG2D CAR T cell activation |
| https://doi.org/10.1136/jitc-2023-sitc2023.0297 | 297 Improvement of CAR T-cell performance by simultaneous downregulation of multiple co-inhibitory receptors |
| https://doi.org/10.1136/jitc-2023-sitc2023.0298 | 298 A miRNA-based shRNA platform for the easy, safe, and effective generation of allogeneic CAR T-cells |
| https://doi.org/10.1302/1358-992x.2024.2.125 | A NEW TISSUE-ENGINEERED PRODUCT INDICATED FOR BONE RECONSTRUCTION: PROOF OF CONCEPT |
| https://doi.org/10.1136/jitc-2024-sitc2024.1133 | 1133 Efficient, safe and customizable modulation of multiple target genes in CAR T cells through a miRNA-based shRNA platform |
| https://doi.org/10.1016/j.jcyt.2025.03.291 | Cryo-processed Leukapheresis Using Automated Closed System: A High-Quality Starting Material for Autologous and Allogeneic CAR-T Cell Therapy Manufacturing. |
| https://doi.org/10.1109/pvsc59419.2025.11132962 | Reliability analysis of perovskite solar modules under space relevant conditions |
| https://doi.org/10.1016/j.omton.2025.201088 | Preclinical development and selection of nanobody-based CAR-T cells targeting HER2-positive solid tumors |
| https://doi.org/10.18609/cgti.2021.130 | Expert Roundtable: analytical tools for cell and gene therapy: what’s new and what’s next? |
| https://doi.org/10.1007/s12265-015-9642-4 | Percutaneous Fluoroscopic-Guided Endomyocardial Delivery in an Experimental Model of Left Ventricular Assist Device Support |